Floatz logo

Sonidegib

Safety

Novartis PharmaceuticalsSmall moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

31 Active assets in the Safety cohort.

Asset / SponsorPhaseRating
Bortezomib
Shandong Provincial Hospital
Phase 4BB
Gemtuzumab Ozogamicin
Pfizer
Phase 4BB
Sodium Oligomannate
First Affiliated Hospital Xi'an Jiaotong University
Phase 4B
Namenda
First Affiliated Hospital Xi'an Jiaotong University
Phase 4B
cc-5013
Shandong Provincial Hospital
Phase 4B

View all 48 →

Same molecule, other indications

Sonidegib is also rated in:

acute leukemiaDormant
B
Indicative ·
57 / 100
View asset →
medulloblastomaDormant
CCC
Indicative ·
54 / 100
View asset →
PTCH1 or SMO Activated Solid and Hematologic TumorsDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →